{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:53Z","timestamp":1787009453516,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","award":["AECC CLSEN20004SERR"],"award-info":[{"award-number":["AECC CLSEN20004SERR"]}]},{"name":"Blueprint Medicines"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gastrointestinal stromal tumors (GISTs) are the most common sarcoma subtype. Patients with unresectable or metastatic GISTs harboring the D842V mutation in the PDGFRA gene have a poor prognosis due to intrinsic resistance to imatinib and all other approved tyrosine kinase inhibitors. Avapritinib, targeting this mutation, is the first agent approved for patients with unresectable or metastatic GIST that have the PDGFRA D842V mutation. This study assesses the effectiveness and safety of avapritinib in real-world clinical scenarios involving Spanish patients with this mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The AVARWE study is a descriptive, retrospective, multicenter observational study of 21 patients treated with avapritinib across 13 Spanish centers from June 9, 2023, to December 18, 2023. Data collected included patient demographics, disease characteristics, treatment history, and response rates based on RECIST criteria. The main outcomes, progression-free survival (PFS) and overall survival (OS), were measured, with safety assessed through adverse events documentation according to CTCAE criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median PFS 35.6 was months and median OS was 42.2 months, with survival rates at 1, 5, and 3 years demonstrating avapritinib effectiveness. The objective response rate was 76.2% for partial response and 4.8% for complete response. Avapritinib enabled surgical intervention in previously unresectable cases and was generally well-tolerated, with manageable adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Avapritinib extends PFS and OS among patients with PDGFRA D842V-mutant GIST in real-world practice, mirroring pivotal trial outcomes. Its substantial activity supports its use as a first-line therapy for this subgroup. The manageable safety profile reinforces avapritinib viability for routine use. Given the rarity of these cases, it is advised to consult sarcoma-expert units.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf062","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:28:42Z","timestamp":1746041322000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation"],"prefix":"10.1093","volume":"30","author":[{"given":"Isaac","family":"Nu\u00f1ez Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Ctra. Gral. del Rosario, 145, 38010 ,","place":["Spain"]},{"name":"Fundaci\u00f3n Investigaci\u00f3n del c\u00e1ncer en Canarias | FICIC ,\u00a0 Av. Alcalde D\u00edaz Saavedra Navarro, 31, 35001 Las Palmas de Gran Canaria, Las Palmas ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"G\u00f3mez Palmero","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Toledo , Toledo, Av. del R\u00edo Guadiana, 45007 ,","place":["Spain"]},{"name":"Hospital Universitario Vall d\u2019Hebron , Pg. de la Vall d'Hebron, 119, Horta-Guinard\u00f3, 08035, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ram\u00f3n","family":"Delgado","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves (HUVN) , Av. de las Fuerzas Armadas, 2, Beiro, 18014 Granada ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA , Av. de Madrid, 15, Beiro, 18012 Granada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nu\u00f1o","sequence":"additional","affiliation":[{"name":"Hospital Obispo Polanco , Av. Ruiz Jarabo, s\/n, 44002, Teruel ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria \u00c1ngeles","family":"Sala Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Basurto , Montevideo Etorb., 18, Basurtu-Zorrotza, 48013, Bilbao ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez Ageitos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Toledo , Toledo, Av. del R\u00edo Guadiana, 45007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda , Carrer del Professor Beltr\u00e1n B\u00e1guena, 8, Campanar, 46009, Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ayala de Miguel","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de C\u00e1ceres , Av. de la Universidad, 75, Norte, 10004 C\u00e1ceres ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Condori","sequence":"additional","affiliation":[{"name":"Hospital Santa B\u00e1rbara de Soria , P\u00ba de Santa B\u00e1rbara, s\/n, 42005, Soria ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D\u00edaz Beveridge","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe , Avinguda de Fernando Abril Martorell, 106, Quatre Carreres, 46026, Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Mart\u00ednez Garc\u00eda","sequence":"additional","affiliation":[{"name":"HCU Virgen de la Arrixaca , Ctra. Madrid-Cartagena, s\/n, 30120 El Palmar, Murcia ,","place":["Spain"]},{"name":"Grupo Investigaci\u00f3n en IMIB- Murcia, Ctra. Madrid-Cartagena, s\/n, 30120 El Palmar,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), Instituto de Investigaci\u00f3n Sanitaria (IdISSC) , Calle del Prof Mart\u00edn Lagos, S\/N, Moncloa - Aravaca, 28040, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Varela-Pose","sequence":"additional","affiliation":[{"name":"University Hospital of Santiago de Compostela (SERGAS) ,\u00a0 R\u00faa da Choupana, s\/n, 15706, Santiago de Compostela ,","place":["Spain"]},{"name":"Translational Medical Oncology Group (Oncomet) , R\u00faa da Choupana, s\/n, 15706, Santiago de Compostela ,","place":["Spain"]},{"name":"Health Research Institute of Santiago de Compostela (IDIS) , R\u00faa da Choupana, s\/n, 15706, Santiago de Compostela ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Veas Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Arnau de Vilanova de Lleida , Av. Alcalde Rovira Roure, 80, 25198, Lleida ,","place":["Spain"]},{"name":"Musgrove Park Hospital, Somerset NHS Foundation Trust , Parkfield Dr, Taunton TA1 5DA, Reino Unido"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-8739","authenticated-orcid":false,"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d\u2019Hebron , Pg. de la Vall d'Hebron, 119, Horta-Guinard\u00f3, 08035, Barcelona ,","place":["Spain"]},{"name":"Vall d\u2019Hebron Institute of Oncology (VHIO) , Carrer de Natzaret 115-117, 08035 Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"2025051102025410800_CIT0001","doi-asserted-by":"publisher","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6","author":"Ducimeti\u00e8re","year":"2011","journal-title":"PLoS One"},{"key":"2025051102025410800_CIT0002","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_351231","article-title":"The GIST of advances in treatment of advanced gastrointestinal stromal tumor","volume":"42","author":"Schaefer","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025051102025410800_CIT0003","doi-asserted-by":"publisher","first-page":"17588359231192388","DOI":"10.1177\/17588359231192388","article-title":"2023 GEIS Guidelines for gastrointestinal stromal tumors","volume":"15","author":"Serrano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2025051102025410800_CIT0004","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"key":"2025051102025410800_CIT0005","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025051102025410800_CIT0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2025051102025410800_CIT0007","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025051102025410800_CIT0008","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025051102025410800_CIT0009","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025051102025410800_CIT0010","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12885-021-08013-1","article-title":"Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data","volume":"21","author":"von Mehren","year":"2021","journal-title":"BMC Cancer"},{"key":"2025051102025410800_CIT0011","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025051102025410800_CIT0012","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2025051102025410800_CIT0013","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2407-12-107","article-title":"The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study","volume":"12","author":"Rutkowski","year":"2012","journal-title":"BMC Cancer"},{"key":"2025051102025410800_CIT0014","doi-asserted-by":"publisher","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025051102025410800_CIT0015","volume-title":"Real Decreto 1090\/2015, de 4 de diciembre, por el que se regulan los ensayos cl\u00ednicos con medicamentos, los Comit\u00e9s de \u00c9tica de la Investigaci\u00f3n con medicamentos y el Registro Espa\u00f1ol de Estudios Cl\u00ednicos"},{"key":"2025051102025410800_CIT0016","volume-title":"Real Decreto 957\/2020, de 3 de noviembre, por el que se regulan los estudios observacionales con medicamentos de uso humano"},{"key":"2025051102025410800_CIT0017","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025051102025410800_CIT0018","article-title":"Common terminology criteria for adverse events (CTCAE) v5.0. National Cancer Institute; November 27","author":"Health UDo, Services H","year":"2017"},{"key":"2025051102025410800_CIT0019","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/annonc\/mds470","article-title":"Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy","volume":"24","author":"Penel","year":"2013","journal-title":"Ann Oncol"},{"key":"2025051102025410800_CIT0020","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025051102025410800_CIT0021","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World evidence - what is it and what can it tell us","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"2025051102025410800_CIT0022","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus in locally advanced unresectable or metastatic gi stromal tumor: A randomized, open-label phase III study","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025051102025410800_CIT0023","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025051102025410800_CIT0024","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","article-title":"Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor","volume":"245","author":"DeMatteo","year":"2007","journal-title":"Ann Surg"},{"key":"2025051102025410800_CIT0025","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"2025051102025410800_CIT0026","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1002\/onco.13632","article-title":"Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors","volume":"26","author":"Joseph","year":"2021","journal-title":"Oncologist"},{"key":"2025051102025410800_CIT0027","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","article-title":"The \u201cEfficacy-Effectiveness Gap\u201d: Historical background and current conceptualization","volume":"19","author":"Nordon","year":"2016","journal-title":"Value Health"},{"key":"2025051102025410800_CIT0028","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/OP.22.00565","article-title":"Real-World first-line use of pertuzumab with different taxanes for human epidermal growth factor receptor 2-positive metastatic breast cancer: A comparative effectiveness study using US electronic health records","volume":"19","author":"Polito","year":"2023","journal-title":"JCO Oncol Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf062\/63142084\/oyaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf062\/63142084\/oyaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T02:03:01Z","timestamp":1746928981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf062\/8128453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf062","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf062"}}